<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090896</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000380840</org_study_id>
    <secondary_id>UCLA-0312023</secondary_id>
    <secondary_id>PFIZER-NRA3670003</secondary_id>
    <nct_id>NCT00090896</nct_id>
  </id_info>
  <brief_title>CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery</brief_title>
  <official_title>A Phase I, Open Label, Study To Evaluate The Safety And Immune Function Effects Of CP-675,206 In Combination With MART-1 Peptide-Pulsed Dendritic Cells In Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as CP-675,206, work in different ways to stimulate the&#xD;
      immune system and stop tumor cells from growing. Vaccines may make the body build an immune&#xD;
      response to kill tumor cells. Combining CP-675,206 with vaccine therapy may cause a stronger&#xD;
      immune response and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of CP-675,206 when&#xD;
      given with vaccine therapy in treating patients with stage III or stage IV melanoma that&#xD;
      cannot be removed with surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and maximum tolerated dose of anti-cytotoxic&#xD;
           T-lymphocyte-associated antigen-4 monoclonal antibody (CTLA4-blocking monoclonal&#xD;
           antibody; CP-675,206) administered with autologous dendritic cells pulsed with MART-1&#xD;
           antigen in patients with unresectable stage III or stage IV melanoma.&#xD;
&#xD;
        -  Determine the biological activity and immune effects of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate CTLA4 genotype with safety of this regimen and/or immune response in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this regimen, in terms of clinical benefit&#xD;
           rate, in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of anti-cytotoxic&#xD;
      T-lymphocyte-associated antigen-4 monoclonal antibody (CTLA4-blocking monoclonal antibody;&#xD;
      CP-675,206).&#xD;
&#xD;
      Patients receive CP-675,206 IV on days 0, 28, 60, and 90 and autologous dendritic cells&#xD;
      pulsed with MART-1 antigen intradermally on days 0, 14, and 28. After day 120, patients with&#xD;
      stable or responding disease may receive additional doses of CP-675,206 monthly in the&#xD;
      absence of disease progression or unacceptable toxicity&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CP-675,206 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-21 patients will be accrued for this study within 3-10&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>CTLA4-Blocking Monoclonal Antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody</intervention_name>
    <arm_group_label>CTLA4-Blocking Monoclonal Antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed cutaneous or mucosal melanoma, meeting criteria for 1 of the&#xD;
             following:&#xD;
&#xD;
          -  Unresectable stage III disease (locally relapsed unresectable, in-transit lesions, or&#xD;
             unresectable draining nodes)&#xD;
&#xD;
          -  Stage IV disease, metastatic to 1 of the following sites:&#xD;
&#xD;
               -  Skin, subcutaneous tissues, or distant lymph nodes&#xD;
&#xD;
               -  Lung&#xD;
&#xD;
               -  Other visceral sites with lactic dehydrogenase ≤ 2 times upper limit of normal&#xD;
                  (unless due to liver stasis)&#xD;
&#xD;
          -  De novo metastatic disease allowed provided patient refused any standard or approved&#xD;
             stage-appropriate therapy for melanoma&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  HLA-A2.1 positive (HLA-A*0201 by molecular subtyping)&#xD;
&#xD;
          -  MART-1-expressing tumor by reverse transcription polymerase chain reaction or&#xD;
             immunohistochemistry&#xD;
&#xD;
          -  No symptomatic brain metastases and/or progression of CNS metastases within the past 4&#xD;
             weeks&#xD;
&#xD;
          -  Age 18 and over&#xD;
&#xD;
          -  Performance status ECOG 0-1 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  More than 30 days since prior immunotherapy for metastatic, relapsed, or primary&#xD;
             melanoma&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy for metastatic, relapsed, or primary&#xD;
             melanoma&#xD;
&#xD;
          -  More than 4 weeks since prior corticosteroids&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy for metastatic, relapsed, or primary&#xD;
             melanoma&#xD;
&#xD;
          -  More than 30 days since prior surgery for metastatic, relapsed, or primary melanoma.&#xD;
&#xD;
          -  More than 30 days since other prior therapy for metastatic, relapsed, or primary&#xD;
             melanoma&#xD;
&#xD;
          -  More than 14 days since prior anti-infective therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immune suppressive therapy (e.g., cyclosporine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic hepatitis B or C&#xD;
&#xD;
          -  asthma&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  celiac disease&#xD;
&#xD;
          -  history of chronic colitis or other chronic gastrointestinal conditions associated&#xD;
             with diarrhea or bleeding&#xD;
&#xD;
          -  active chronic inflammatory or autoimmune disease, including any of the following:&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  Hashimoto's thyroiditis&#xD;
&#xD;
          -  Addison's disease&#xD;
&#xD;
          -  Graves' disease&#xD;
&#xD;
          -  Systemic lupus erythematosus&#xD;
&#xD;
          -  active infection OR fever over 100° F within the past 3 days&#xD;
&#xD;
          -  allergy to study drugs&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  symptomatic seizures&#xD;
&#xD;
          -  other medical problem that would preclude study participation&#xD;
&#xD;
          -  prior melanoma immunotherapy containing MART-1 antigen&#xD;
&#xD;
          -  prior anti-T-cell therapy&#xD;
&#xD;
          -  prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody&#xD;
             (CP-675,206)&#xD;
&#xD;
          -  organ allografts requiring long-term immune suppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Ribas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

